Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jun 23, 2024 10:49am
60 Views
Post# 36102180

RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion" Tumor-infiltrating lymphocytes (TILs): These lymphocytes primarily comprise cytotoxic (CD8+) and helper (CD4+) T cells and a smaller proportion of B and NK cells. Their functions can dynamically change throughout tumor progression and in response to anticancer therapy. The presence of lymphocytes in tumors is often associated with a better clinical outcome " - ( Luigi Ippolito, ... Paola Chiarugi,  2022)

TILs are found in stroma within tumor area and contain T cells, B cells, NK cells and macrophages. TILs are important for diagnosis and prognosis in patients with many solid tumors . TILs can be classified as intratumoral (itTIL), lymphocytes localized in tumor nests having direct cell-to-cell contact, and stromal (sTIL), present in the stroma between tumor cells 

Tumor infiltrating lymphocytes (TILs) is an important biomarker in tumor immunotherapeutic treatment, which refers to lymphocytes that gathered around adjacent tissue stroma or within focal areas. For breast cancer, TNBC has a higher level of TILs, followed by HER-2 positive breast cancer, and hormone receptor positive/HER-2 negative TILs are relatively the lowest.


<< Previous
Bullboard Posts
Next >>